KR20180084996A - 신규 비페닐 화합물 또는 그의 염 - Google Patents

신규 비페닐 화합물 또는 그의 염 Download PDF

Info

Publication number: KR20180084996A
Authority: KR; South Korea
Prior art keywords: salt; biphenyl compound; novel biphenyl; novel; compound
Prior art date: 2015-11-27

Application number

KR1020187017813A

Other languages

English (en)

Other versions

KR102204748B1 (ko

Inventor

사토시 야마시타

다카히로 오가와

히데야 고마타니

Original Assignee

다이호야쿠힌고교 가부시키가이샤

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-27

Filing date

2016-11-25

Publication date

2018-07-25

2016-11-25 Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤

2018-07-25 Publication of KR20180084996A publication Critical patent/KR20180084996A/ko

2021-01-19 Application granted granted Critical

2021-01-19 Publication of KR102204748B1 publication Critical patent/KR102204748B1/ko

Links

0 *CCc1cc(C(*)=O)ccc1N=O Chemical compound *CCc1cc(C(*)=O)ccc1N=O 0.000 description 4
FRXHSLXFNJYCTP-IBTOBYAESA-N C=CC1(C2)C3C2C(C[C@H](C2)C4NC2CCC4)CC3C1 Chemical compound C=CC1(C2)C3C2C(C[C@H](C2)C4NC2CCC4)CC3C1 FRXHSLXFNJYCTP-IBTOBYAESA-N 0.000 description 1
RYQMWCGSNXLJOY-UHFFFAOYSA-N CC(C1)CC2C1CNC2 Chemical compound CC(C1)CC2C1CNC2 RYQMWCGSNXLJOY-UHFFFAOYSA-N 0.000 description 1
LLAMAEIOZLEXMF-UHFFFAOYSA-N CN1C(CC2)CC2C1 Chemical compound CN1C(CC2)CC2C1 LLAMAEIOZLEXMF-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Hydrogenated Pyridines (AREA)

KR1020187017813A 2015-11-27 2016-11-25 신규 비페닐 화합물 또는 그의 염 KR102204748B1 (ko)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP2015232009		2015-11-27
JPJP-P-2015-232009		2015-11-27
JP2016117454		2016-06-13
JPJP-P-2016-117454		2016-06-13
PCT/JP2016/085067 WO2017090756A1 (ja)	2015-11-27	2016-11-25	新規なビフェニル化合物又はその塩

Publications (2)

Publication Number	Publication Date
KR20180084996A true KR20180084996A (ko)	2018-07-25
KR102204748B1 KR102204748B1 (ko)	2021-01-19

Family

ID=58763300

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020187017813A KR102204748B1 (ko)	2015-11-27	2016-11-25	신규 비페닐 화합물 또는 그의 염

Country Status (20)

Country	Link
US (1)	US10723742B2 (ko)
EP (1)	EP3381896B1 (ko)
JP (1)	JP6510068B2 (ko)
KR (1)	KR102204748B1 (ko)
CN (1)	CN108602770B (ko)
AU (1)	AU2016360481B2 (ko)
CA (1)	CA3006434C (ko)
DK (1)	DK3381896T3 (ko)
ES (1)	ES2939609T3 (ko)
FI (1)	FI3381896T3 (ko)
HU (1)	HUE061698T2 (ko)
MA (1)	MA43318A (ko)
MX (1)	MX2018006503A (ko)
PH (1)	PH12018501099A1 (ko)
PL (1)	PL3381896T3 (ko)
PT (1)	PT3381896T (ko)
RU (1)	RU2726622C2 (ko)
SG (1)	SG11201804121RA (ko)
TW (1)	TWI679195B (ko)
WO (1)	WO2017090756A1 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20200008611A (ko) *	2017-05-26	2020-01-28	다이호야쿠힌고교 가부시키가이샤	신규 비페닐 화합물을 사용한 항종양 효과 증강제
KR20200009068A (ko) *	2017-05-26	2020-01-29	다이호야쿠힌고교 가부시키가이샤	신규 비페닐 화합물 또는 그의 염

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2939609T3 (es)	2015-11-27	2023-04-25	Taiho Pharmaceutical Co Ltd	Compuesto de bifenilo o sal del mismo
WO2018083189A1 (en)	2016-11-03	2018-05-11	Oryzon Genomics, S.A.	Biomarkers for determining responsiveness to lsd1 inhibitors
US20200190175A1 (en) *	2017-05-31	2020-06-18	Taiho Pharmaceutical Co., Ltd.	Method for predicting therapeutic effect of lsd1 inhibitor based on expression of insm1
AU2018309372A1 (en)	2017-08-03	2020-01-30	Oryzon Genomics, S.A.	Methods of treating behavior alterations
AR112900A1 (es)	2017-09-13	2019-12-26	Hanmi Pharm Ind Co Ltd	Compuesto derivado de pirazol y uso de este
CA3092362A1 (en) *	2017-10-19	2019-04-25	Tempest Therapeutics, Inc.	Picolinamide compounds
CN113631164A (zh)	2019-03-20	2021-11-09	奥莱松基因组股份有限公司	使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
KR20210141933A (ko)	2019-03-20	2021-11-23	오리존 지노믹스 에스.에이.	경계성 인격 장애의 치료 방법
WO2021004610A1 (en)	2019-07-05	2021-01-14	Oryzon Genomics, S.A.	Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
CN110759831B (zh) *	2019-10-16	2022-09-27	浙江金伯士药业有限公司	制备常山酮中间体2-氨基-4-溴-5-氯苯甲酸方法
US20220411368A1 (en)	2019-11-13	2022-12-29	Taiho Pharmaceutical Co., Ltd.	Novel salt of terphenyl compound
WO2022199662A1 (zh) *	2021-03-24	2022-09-29	四川汇宇制药股份有限公司	一种多环化合物及其应用
WO2022214303A1 (en)	2021-04-08	2022-10-13	Oryzon Genomics, S.A.	Combinations of lsd1 inhibitors for treating myeloid cancers
TW202308991A (zh) *	2021-05-11	2023-03-01	美商亞士德製藥公司	三苯化合物之固體形式
WO2023054547A1 (en) *	2021-09-30	2023-04-06	Taiho Pharmaceutical Co., Ltd.	Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator
WO2023076302A1 (en)	2021-10-26	2023-05-04	Astex Pharmaceuticals, Inc.	Process for preparing a benzoate salt of a 1-(3-aminopyrrolidine-1-carbonyl)-3,4-diphenylbenzene compound
WO2023217758A1 (en)	2022-05-09	2023-11-16	Oryzon Genomics, S.A.	Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en)	2022-05-09	2023-11-16	Oryzon Genomics, S.A.	Methods of treating nf1-mutant tumors using lsd1 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010077624A1 (en)	2008-12-09	2010-07-08	Merck Sharp & Dohme Corp.	Biaryl carboxamides
WO2014151761A1 (en) *	2013-03-15	2014-09-25	Ariad Pharmaceuticals, Inc.	Novel choline kinase inhibitors
WO2015089192A1 (en)	2013-12-11	2015-06-18	Quanticel Pharmaceuticals, Inc.	Inhibitors of lysine specific demethylase-1
WO2015103060A1 (en)	2014-01-06	2015-07-09	Algomedix, Inc.	Trpa1 modulators
WO2015168466A1 (en)	2014-05-01	2015-11-05	Quanticel Pharmaceuticals, Inc.	Inhibitors of lysine specific demethylase-1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8163509B2 (en)	2008-10-20	2012-04-24	The Regents Of The University Of Colorado, A Body Corporate	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2419177A1 (en)	2009-04-17	2012-02-22	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
NZ602055A (en) *	2010-03-25	2014-08-29	Abbvie Inc	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102985402B (zh)	2010-04-20	2015-04-29	罗马大学	反苯环丙胺衍生物作为组蛋白去甲基酶lsd1和/或lsd2的抑制剂
JP6054868B2 (ja)	2010-07-29	2016-12-27	オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎＧｅｎｏｍｉｃｓＳ．Ａ．	Ｌｓｄ１のアリールシクロプロピルアミンをベースとしたデメチラーゼ阻害剤およびそれらの医学的使用
CN104185420B (zh) *	2011-11-30	2017-06-09	埃默里大学	用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
US9790195B2 (en)	2013-08-06	2017-10-17	Imago Biosciences, Inc.	KDM1A inhibitors for the treatment of disease
CN103893163B (zh) *	2014-03-28	2016-02-03	中国药科大学	2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
WO2016007727A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US10485772B2 (en)	2014-08-25	2019-11-26	EpiAxis Therapeutics Pty Ltd.	Compositions for modulating cancer stem cells and uses therefor
WO2016037005A1 (en)	2014-09-05	2016-03-10	Quanticel Pharmaceuticals, Inc.	Inhibitors of lysine specific demethylase-1
WO2017013061A1 (en)	2015-07-17	2017-01-26	Oryzon Genomics, S.A.	Biomarkers associated with lsd1 inhibitors and uses thereof
ES2939609T3 (es)	2015-11-27	2023-04-25	Taiho Pharmaceutical Co Ltd	Compuesto de bifenilo o sal del mismo
US11510915B2 (en)	2017-05-26	2022-11-29	Taiho Pharmaceutical Co., Ltd.	Anti-tumor effect potentiator using novel biphenyl compound
RU2765152C2 (ru)	2017-05-26	2022-01-26	Тайхо Фармасьютикал Ко., Лтд.	Новое соединение бифенила или его соль
US20200190175A1 (en)	2017-05-31	2020-06-18	Taiho Pharmaceutical Co., Ltd.	Method for predicting therapeutic effect of lsd1 inhibitor based on expression of insm1

2016
- 2016-11-25 ES ES16868699T patent/ES2939609T3/es active Active
- 2016-11-25 SG SG11201804121RA patent/SG11201804121RA/en unknown
- 2016-11-25 EP EP16868699.6A patent/EP3381896B1/en active Active
- 2016-11-25 JP JP2017552746A patent/JP6510068B2/ja active Active
- 2016-11-25 HU HUE16868699A patent/HUE061698T2/hu unknown
- 2016-11-25 WO PCT/JP2016/085067 patent/WO2017090756A1/ja active Application Filing
- 2016-11-25 TW TW105138929A patent/TWI679195B/zh active
- 2016-11-25 PL PL16868699.6T patent/PL3381896T3/pl unknown
- 2016-11-25 CN CN201680080157.7A patent/CN108602770B/zh active Active
- 2016-11-25 PT PT168686996T patent/PT3381896T/pt unknown
- 2016-11-25 DK DK16868699.6T patent/DK3381896T3/da active
- 2016-11-25 CA CA3006434A patent/CA3006434C/en active Active
- 2016-11-25 AU AU2016360481A patent/AU2016360481B2/en active Active
- 2016-11-25 US US15/776,548 patent/US10723742B2/en active Active
- 2016-11-25 MA MA043318A patent/MA43318A/fr unknown
- 2016-11-25 MX MX2018006503A patent/MX2018006503A/es unknown
- 2016-11-25 RU RU2018121834A patent/RU2726622C2/ru active
- 2016-11-25 FI FIEP16868699.6T patent/FI3381896T3/fi active
- 2016-11-25 KR KR1020187017813A patent/KR102204748B1/ko active IP Right Grant
2018
- 2018-05-22 PH PH12018501099A patent/PH12018501099A1/en unknown

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010077624A1 (en)	2008-12-09	2010-07-08	Merck Sharp & Dohme Corp.	Biaryl carboxamides
WO2014151761A1 (en) *	2013-03-15	2014-09-25	Ariad Pharmaceuticals, Inc.	Novel choline kinase inhibitors
WO2015089192A1 (en)	2013-12-11	2015-06-18	Quanticel Pharmaceuticals, Inc.	Inhibitors of lysine specific demethylase-1
WO2015103060A1 (en)	2014-01-06	2015-07-09	Algomedix, Inc.	Trpa1 modulators
WO2015168466A1 (en)	2014-05-01	2015-11-05	Quanticel Pharmaceuticals, Inc.	Inhibitors of lysine specific demethylase-1

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biochim. Biophys. Acta, 1829(10), P.981-986(2013)
Cancer Cell, 21(4), P.473-487(2012)
Cancer Cell, 28(1), P.57-69(2015)
Epigenomics, 7(4), P.609-626(2015)
Nat. Med., 19(3), P.291-294(2013)
Sci. Transl. Med., 6(265), 265ra169(2014)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20200008611A (ko) *	2017-05-26	2020-01-28	다이호야쿠힌고교 가부시키가이샤	신규 비페닐 화합물을 사용한 항종양 효과 증강제
KR20200009068A (ko) *	2017-05-26	2020-01-29	다이호야쿠힌고교 가부시키가이샤	신규 비페닐 화합물 또는 그의 염

Also Published As

Publication number	Publication date
CA3006434C (en)	2021-03-16
WO2017090756A1 (ja)	2017-06-01
AU2016360481A1 (en)	2018-06-07
CN108602770B (zh)	2022-02-08
FI3381896T3 (fi)	2023-04-21
EP3381896A1 (en)	2018-10-03
TWI679195B (zh)	2019-12-11
DK3381896T3 (da)	2023-03-27
AU2016360481B2 (en)	2019-09-12
RU2018121834A3 (ko)	2020-01-09
HUE061698T2 (hu)	2023-08-28
JPWO2017090756A1 (ja)	2018-06-14
ES2939609T3 (es)	2023-04-25
RU2018121834A (ru)	2020-01-09
EP3381896A4 (en)	2019-07-17
PT3381896T (pt)	2023-03-06
US10723742B2 (en)	2020-07-28
EP3381896B1 (en)	2023-01-18
BR112018010371A2 (pt)	2018-12-04
MX2018006503A (es)	2019-02-20
RU2726622C2 (ru)	2020-07-15
JP6510068B2 (ja)	2019-05-08
PL3381896T3 (pl)	2023-05-08
US20180354960A1 (en)	2018-12-13
CA3006434A1 (en)	2017-06-01
SG11201804121RA (en)	2018-06-28
TW201726615A (zh)	2017-08-01
MA43318A (fr)	2018-10-03
CN108602770A (zh)	2018-09-28
PH12018501099A1 (en)	2019-01-28
KR102204748B1 (ko)	2021-01-19

Legal Events

Date	Code	Title
2018-06-22	A201	Request for examination
2018-06-22	AMND	Amendment
2019-10-28	E902	Notification of reason for refusal
2019-12-13	AMND	Amendment
2020-03-11	E902	Notification of reason for refusal
2020-05-07	AMND	Amendment
2020-07-07	E601	Decision to refuse application
2020-09-29	AMND	Amendment
2020-10-20	X701	Decision to grant (after re-examination)
2021-01-13	GRNT	Written decision to grant

Publication	Publication Date	Title
KR20180084996A (ko)	2018-07-25	신규 비페닐 화합물 또는 그의 염
NO2024007I1 (no)	2024-02-21	Elacestrant or a salt thereof
DK3316969T3 (da)	2022-05-02	Antibakterielle forbindelser
BR112017020873A2 (pt)	2018-07-17	misturas herbicidas
DK3160950T3 (da)	2020-08-03	Herbicide propynylphenylforbindelser
DK3298027T3 (da)	2021-08-09	Anthelmintiske depsipeptidforbindelser
BR112017005883A2 (pt)	2018-06-26	compostos herbicidas
DK3612519T3 (da)	2022-03-07	Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
BR112017017193A2 (pt)	2018-06-26	compostos herbicidas
CL2016002165A1 (es)	2017-06-09	Compuestos de aminocarbonilcarbamato
SG11201604954YA (en)	2016-07-28	Novel tetrahydropyridopyrimidine compound or salt thereof
BR112016030730A2 (pt)	2017-08-22	Composto
MA51576A (fr)	2020-11-18	Polythérapie
BR112016029117A2 (pt)	2017-10-17	compostos herbicidas
BR112017023150A2 (pt)	2018-07-10	compostos herbicidas.
DK3191466T3 (da)	2020-01-20	Azetidinyloxyphenylpyrrolidinforbindelser
DK3597189T3 (da)	2022-06-27	Krystallinske forbindelser
MA43275A (fr)	2018-09-26	Composé de pyranodipyridine
DK3344664T3 (da)	2019-12-09	Biocide blandinger
DK3472163T3 (da)	2021-02-01	Chelatforbindelser
DK3347403T3 (da)	2020-06-29	Polyalkoxyfedtforbindelse
DK3672941T3 (da)	2022-05-09	Pyridylpyridonforbindelser
DK3317248T3 (da)	2020-12-14	Sacubitrilcalciumsalte
BR112018001062A2 (pt)	2018-09-11	compostos inovadores
DK3412667T3 (da)	2022-01-10	Cokrystal

KR20180084996A - 신규 비페닐 화합물 또는 그의 염 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Publications (2)

Family

ID=58763300

Family Applications (1)

Country Status (20)

Cited By (2)

Families Citing this family (18)

Citations (5)

Family Cites Families (16)

Patent Citations (5)

Non-Patent Citations (6)

Cited By (2)

Also Published As

Similar Documents

Legal Events